Stocks · Health care · Biological Products, (No Diagnostic Substances)

Lexeo Therapeutics, Inc.

LXEO Clue Score11
United States Fiscal year ends December CIK 0001907108 Results filed 12 Aug 2026

What the insiders did Net selling

By person

9 insiders · 16 transactions
2.9×

R. Nolan Townsend holds only 2.9 times base salary in stock. $1.87M of shares against $632.70K in salary for 2025.

Salary from the company's own proxy. The shares are what R. Nolan Townsend last reported holding, valued at $4.96, the price Common Stock was last bought or sold at on the open market here, on 18 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Richard Nolan Townsend
Chief Executive Officer
—
$538.24K (6) scheduled
−$538.24K
376,778
$1.87M
+208.0%
Narinder Pal Bhalla
Chief Medical Officer
—
$98.59K (1)
−$98.59K
84,908
$420.90K
—
Jose Manuel Otero
Chief Operating Officer
—
$53.27K (4)
−$53.27K
138,288
$685.51K
+342.5%
Louis Edward Tamayo
Chief Financial Officer
—
$41.04K (2)
−$41.04K
92,907
$460.55K
—
Eric Adler
Chief Medical Officer
—
$5.70K (1)
−$5.70K
72,646
$360.11K
+170.3%
Jenny Robertson
Chief Legal Officer
—
$5.09K (1)
−$5.09K
68,381
$338.97K
+187.9%
Tai Sandi See
Chief Development Officer
—
$3.58K (1)
−$3.58K
65,476
$324.57K
+293.8%
Kyle Rasbach
Chief Financial Officer
—
—
—
40,875
$202.62K
—
Paula H Cholmondeley
Director
—
—
—
30,627
$151.82K
+96.0%

No percentages here. This company's share count has moved by a factor of 2.5 over the window, from 33,196,997 to 82,046,255 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.